CEO research orientation, organizational context, and innovation in the pharmaceutical industry

Nino van de Wal; Christophe Boone; Victor Gilsing; Bob Walrave

doi:10.1111/radm.12394

CEO research orientation, organizational context, and innovation in the pharmaceutical industry

Nino van de Wal
, Christophe Boone
, Victor Gilsing
, Bob Walrave^*

^*Corresponding author for this work

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

This study develops and tests a comprehensive framework that explains what, when, and how CEO characteristics influence firms’ innovation outcomes in R&D-intensive industries. Empirical evidence from 109 CEOs from 87 U.S.-based pharmaceutical firms over the period 2001–2013 reveals that research-oriented CEOs – those with ability and motivation for science and technology – increase their firms’ innovation outcomes. The results indicate that the CEO–innovation relationship strongly depends on the extent of CEOs’ managerial discretion, which is shaped by the organizational context. We contribute to a more comprehensive understanding of the role of CEOs in firms´ innovation performance differentials.

Original language	English
Pages (from-to)	239-254
Number of pages	16
Journal	R&D Management
Volume	50
Issue number	2
Early online date	16 Oct 2019
DOIs	https://doi.org/10.1111/radm.12394
Publication status	Published - 1 Mar 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 9 Industry, Innovation, and Infrastructure

Access to Document

10.1111/radm.12394

Persistent URL (handle)

Persistent link

Cite this

@article{550c8f0ae4094743be69c8e35266cbe3,

title = "CEO research orientation, organizational context, and innovation in the pharmaceutical industry",

abstract = "This study develops and tests a comprehensive framework that explains what, when, and how CEO characteristics influence firms{\textquoteright} innovation outcomes in R\&D-intensive industries. Empirical evidence from 109 CEOs from 87 U.S.-based pharmaceutical firms over the period 2001–2013 reveals that research-oriented CEOs – those with ability and motivation for science and technology – increase their firms{\textquoteright} innovation outcomes. The results indicate that the CEO–innovation relationship strongly depends on the extent of CEOs{\textquoteright} managerial discretion, which is shaped by the organizational context. We contribute to a more comprehensive understanding of the role of CEOs in firms´ innovation performance differentials.",

author = "\{van de Wal\}, Nino and Christophe Boone and Victor Gilsing and Bob Walrave",

year = "2020",

month = mar,

day = "1",

doi = "10.1111/radm.12394",

language = "English",

volume = "50",

pages = "239--254",

journal = "R\&D Management",

issn = "0033-6807",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

TY - JOUR

T1 - CEO research orientation, organizational context, and innovation in the pharmaceutical industry

AU - van de Wal, Nino

AU - Boone, Christophe

AU - Gilsing, Victor

AU - Walrave, Bob

PY - 2020/3/1

Y1 - 2020/3/1

N2 - This study develops and tests a comprehensive framework that explains what, when, and how CEO characteristics influence firms’ innovation outcomes in R&D-intensive industries. Empirical evidence from 109 CEOs from 87 U.S.-based pharmaceutical firms over the period 2001–2013 reveals that research-oriented CEOs – those with ability and motivation for science and technology – increase their firms’ innovation outcomes. The results indicate that the CEO–innovation relationship strongly depends on the extent of CEOs’ managerial discretion, which is shaped by the organizational context. We contribute to a more comprehensive understanding of the role of CEOs in firms´ innovation performance differentials.

AB - This study develops and tests a comprehensive framework that explains what, when, and how CEO characteristics influence firms’ innovation outcomes in R&D-intensive industries. Empirical evidence from 109 CEOs from 87 U.S.-based pharmaceutical firms over the period 2001–2013 reveals that research-oriented CEOs – those with ability and motivation for science and technology – increase their firms’ innovation outcomes. The results indicate that the CEO–innovation relationship strongly depends on the extent of CEOs’ managerial discretion, which is shaped by the organizational context. We contribute to a more comprehensive understanding of the role of CEOs in firms´ innovation performance differentials.

UR - https://www.scopus.com/pages/publications/85074355108

UR - https://www.scopus.com/pages/publications/85074355108#tab=citedBy

U2 - 10.1111/radm.12394

DO - 10.1111/radm.12394

M3 - Article

AN - SCOPUS:85074355108

SN - 0033-6807

VL - 50

SP - 239

EP - 254

JO - R&D Management

JF - R&D Management

IS - 2

ER -

CEO research orientation, organizational context, and innovation in the pharmaceutical industry

Abstract

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this